ID BID007 AC CVCL_W890 SY Beth Israel Deaconess 007 DR cancercelllines; CVCL_W890 DR Cosmic; 2093906 DR Wikidata; Q54796550 RX PubMed=24353160; RX PubMed=31467113; CC Sequence variation: Mutation; HGNC; HGNC:3236; EGFR; Simple; p.Ala763_Tyr764insPheGlnGluAla (c.2284-5_2290dup); ClinVar=VCV000045248; Zygosity=Unspecified (PubMed=24353160). CC Omics: Variations; CNV analysis. CC Derived from site: Metastatic; Pleural effusion; UBERON=UBERON_0000175. DI NCIt; C3512; Lung adenocarcinoma OX NCBI_TaxID=9606; ! Homo sapiens (Human) SX Female CA Cancer cell line DT Created: 17-07-14; Last updated: 10-04-25; Version: 11 // RX PubMed=24353160; DOI=10.1126/scitranslmed.3007205; PMCID=PMC3954775; RA Yasuda H., Park E., Yun C.-H., Sng N.J., Lucena-Araujo A.R., RA Yeo W.-L., Huberman M.S., Cohen D.W., Nakayama S., Ishioka K., RA Yamaguchi N., Hanna M., Oxnard G.R., Lathan C.S., Moran T., RA Sequist L.V., Chaft J.E., Riely G.J., Arcila M.E., Soo R.A., RA Meyerson M.L., Eck M.J., Kobayashi S.S., Costa D.B.; RT "Structural, biochemical, and clinical characterization of epidermal RT growth factor receptor (EGFR) exon 20 insertion mutations in lung RT cancer."; RL Sci. Transl. Med. 5:216ra177.1-216ra177.10(2013). // RX PubMed=31467113; DOI=10.1158/1541-7786.MCR-19-0419; PMCID=PMC6872223; RA Udagawa H., Hasako S., Ohashi A., Fujioka R., Hakozaki Y., Shibuya M., RA Abe N., Komori T., Haruma T., Terasaka M., Fujita R., Hashimoto A., RA Funabashi K., Yasuda H., Miyadera K., Goto K., Costa D.B., RA Kobayashi S.S.; RT "TAS6417/CLN-081 is a pan-mutation-selective EGFR tyrosine kinase RT inhibitor with a broad spectrum of preclinical activity against RT clinically relevant EGFR mutations."; RL Mol. Cancer Res. 17:2233-2243(2019). //